JITC Digest December 2018

jitc-logo.gif

Inside this Issue:

Letter from the Editor

Dear JITC Readers,pedro-romero_1__1_.jpg

In the December edition of the JITC Digest, there are six notable articles of which I would like to draw special attention. First, the article “STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial,” by Matthew J. Reilley et al. reports novel phase 1b clinical trial data on the use of AZD9150, a next generation antisense oligonucleotide STAT3 inhibitor, for the treatment of heavily pretreated patients with diffuse large B-cell lymphoma (DLBCL). With prior evidence for STAT3 indicative of immune modulation and promotion of tumor immune evasion, this study suggests a key role for STAT3 as an anticancer target.

Another novel immunotherapeutic agent is featured in the article “Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma,” by Ian Lai et al. The article investigates the use of an mRNA lipid nanoparticle-based approach for the in situ delivery and production of IL-12 (IL-12-LNP) in a murine model of refractory MYC-driven hepatocellular carcinoma (HCC). As overexpression of the MYC oncogene is a common feature of aggressive human HCCs, this article describes a potentially relevant pre-clinical model for determination of the effectiveness of IL-12-LNP as a non-toxic alternative to MYC inhibition in the treatment of aggressive HCCs.

Next, the workshop report, “Immuno-Oncology Biomarkers: State of the Art,” highlights a two-day immunotherapy-based biomarkers workshop hosted by the Society for Immunotherapy of Cancer (SITC), which brought together immuno-oncology experts to discuss new developments and technologies, associated challenges and future collaborations in the field of cancer biomarkers. Attendees discussed how breakthroughs in immunotherapy are redefining how clinicians approach patient care, and the need to target new biomarkers to drive therapeutic development. Interestingly, Aixa E. Soyano et al. also reports on the utilization of biomarkers in supporting immunotherapy treatment strategies. In their article, “Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies,” Dr. Soyano’s group presents findings related to the potential predictive value of peripheral blood biomarkers in patients with NSCLC.

Furthermore, the review, “Soluble immune checkpoints in cancer: production, function and biological significance,” by Daqian Gu et al. presents an overview of soluble immune checkpoints, receptors and ligands found free in the plasma which play an important role in immune regulation, prognosis of cancer, and as potential biomarkers and therapeutic targets. This intriguing article provides a detailed and potentially useful review of the functionality and clinical influence of these soluble molecules in the formation of immunotherapeutic strategies.

Finally, Michael M. Boyiadzis et al.’s review, “Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance,” details the recent scientific research, clinical trial data and FDA approvals surrounding the revolutionary Chimeric Antigen Receptor (CAR) T cell technologies. Specifically, this review discusses important topics, such as toxicity management, that may be used for reference by treating clinicians.

With best regards,
Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer


Immunotherapy in the News

Nobel laureates in Physiology or Medicine James P. Allison, PhD, and Tasuku Honjo, MD, PhD, delivered their lectures "Immune Checkpoint Blockade in Cancer Therapy: New insights, opportunities, and prospects for cures" and "Serendipities of acquired immunity," respectively, in Solna, Sweden on Friday, Dec. 7, 2018. Watch their lectures and then read articles from additional leading experts in JITC’s Immune Checkpoint Therapy collection.


Recent Articles

Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer

May Tun Saung, Stephen Muth, Ding Ding, Dwayne L. Thomas II, Alex B. Blair, Takahiro Tsujikawa, Lisa Coussens, Elizabeth M. Jaffee and Lei Zheng
Journal for ImmunoTherapy of Cancer, 6:118 (13 November 2018)
Research Article

From the Authors

"Our study demonstrated that blocking myeloid cells through an antibody targeting CSF1R, in combination with anti-PD-1 antibody, is able to convert PD-1 positive T-cells, which are induced by a cancer vaccine, into activated and functional T-cells, as well as expand this population of cytotoxic T-cells within the tumors in a mouse model of pancreatic cancer."

Lei Zheng, MD, PhD — Johns Hopkins University School of Medicine

Immune checkpoint inhibitor-related acral vasculitis

Thibault Comont, Vincent Sibaud, Loïc Mourey, Pierre Cougoul and Odile Beyne-Rauzy
Journal for ImmunoTherapy of Cancer, 6:120 (16 November 2018)
Commentary

From the Authors

"In response to “Ipilimumab induced vasculitis” by Padda A. et al., J Immunother Cancer. 2018;6:12, we report a new case of a small vasculitis with digital necrosis as an immune related adverse event secondary to immune checkpoint inhibitors (ICI). In contrast to Padda's report we add some different findings: combination of ICI with new molecules, very good outcome after treatment with steroids, stability of cancer despite ICI withdraw. We also summarize others reports previously published."

Thibault Comont, MD — Institut Universitaire du Cancer Toulouse Oncopole

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina Piha-Paul, Murali V. P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey Revenko, Brett P. Monia, A. Robert MacLeod and David S. Hong
Journal for ImmunoTherapy of Cancer, 6:119 (16 November 2018)
Research Article

From the Authors

"AZD9150 (danvatirsen) is a novel antisense oligonucleotide targeting STAT3. This paper showed for the first time the potential of danvatirsen and its effect as a possible immunotherapeutic agent. Recently, data from the SCORES study of danvatirsen and durvalumab (antiPDL-1 inhibitor) presented at ESMO 2018 showed promising activity in 2nd line head and neck cancer patients with an overall response rate of 26%. These results suggests enhanced activity of the combination and prompt further studies."

David S. Hong, MD — The University of Texas MD Anderson Cancer Center

Immunoregulatory functions of innate lymphoid cells

Sarah Q. Crome and Pamela S. Ohashi
Journal for ImmunoTherapy of Cancer, 6:121 (19 November 2018)
Commentary

Excerpt:

"The mechanisms behind [innate lymphoid cells] ILC-mediated regulation are only beginning to be understood, but emerging evidence supports that in addition to indirect regulation via cytokine production or effects on antigen presenting cells or other ILCs, direct ILC-T cell interactions shape the outcome of different immune responses."

Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab

David M. Miller, Ryan M. Trowbridge, Anupam Desai and Reed E. Drews
Journal for ImmunoTherapy of Cancer, 6:122 (19 November 2018)
Case Report

From the Authors

"This case highlights the complexities of caring for patients with coexistent cancers by demonstrating the rapid progression of primary cutaneous anaplastic large cell lymphoma following checkpoint inhibitor therapy for metastatic melanoma and introduces a novel adverse effect of oncolytic viral therapy: Kaposi’s varicelliform eruption."

David M. Miller, MD, PhD — Beth Israel Deaconess Medical Center

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer

Fanny Ledys, Quentin Klopfenstein, Caroline Truntzer, Laurent Arnould, Julie Vincent, Leila Bengrine, Romain Remark, Romain Boidot, Sylvain Ladoire, François Ghiringhelli and Valentin Derangere
Journal for ImmunoTherapy of Cancer, 6:123 (19 November 2018)
Research Article

From the Authors

"T cells infiltrates are known to impact on colorectal cancer prognostic in both localized and metastatic tumor, but the effect of RAS mutation and chemotherapy is poorly known. Using a retrospective cohort of 114 patients treated by surgery of liver metastasis of colorectal cancer we observed that high CD8+ cells infiltrate and high HLA-I expression were associated with a better overall survival in both univariate and multivariate model. Moreover, CD8+ cells immune infiltrate at invasive margin combined to HLA expression in cancer cell could increase patient’s outcome prediction.

RAS status was associated with HLA expression on tumor cells but not with immune cell infiltration. In comparison to untreated patients, neoadjuvant chemotherapy induced CD8+ cells recruitment and increased PD-L1 staining in immune infiltrates only for wild type RAS patients. In this context, anti-EGFR and oxaliplatin based chemotherapy are the most powerful to induce CD8+ cells mobilization within the metastatic site. Together these data underline that CD8 infiltrate and HLA expression are prognostic for metastatic colorectal cancer, CD8 and PD-L1 infiltrate are enhanced by neoadjuvant chemotherapy under RAS status dependence."

François Ghiringhelli, MD, PhD — Institut National De La Sante Et De Le Recherche Medicale (INSERM)

Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

Bin Wu, Qiang Zhang and Jie Sun
Journal for ImmunoTherapy of Cancer, 6:124 (20 November 2018)
Research Article

From the Authors

"The high costs of immune checkpoint inhibitors are concerned by decision-makers. This article found nivolumab plus ipilimumab as first-line treatment could gain more health benefits for advanced RCC in comparison with standard sunitinib, which is considered to be cost-effective in the US and China but not in the UK. To improve the affordability, we recommend the producers reduce the costs of immune checkpoint inhibitors."

Jie Sun — Shanghai Jiaotong University

Acquired resistance to immunotherapy in MMR-D pancreatic cancer

Zishuo Ian Hu, Matthew D. Hellmann, Jedd D. Wolchok, Monika Vyas, Jinru Shia, Zsofia K. Stadler, Luis A. Diaz Jr and Eileen M. O’Reilly
Journal for ImmunoTherapy of Cancer, 6:127 (20 November 2018)
Case Report

From the Authors

"A small subset of patients with pancreas ductal adenocarcinoma have mismatch repair deficiency (approx 1%). These are important individuals to identify from the targeted therapeutic perspective and from the perspective of family genetic screening. This report comments on potential mechanisms of resistance to immunotherapy in a patient with MSI-H pancreas adenocarcinoma receiving checkpoint inhibitor therapy."

Eileen M. O'Reilly, MD — Memorial Sloan Kettering Cancer Center

Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature

Francesco Sabbatino, Antonio Marra, Luigi Liguori, Giosuè Scognamiglio, Celeste Fusciello, Gerardo Botti, Soldano Ferrone and Stefano Pepe
Journal for ImmunoTherapy of Cancer, 6:126 (20 November 2018)
Case Report

About:

"Although preclinical evidence suggests a potential role of immune checkpoint inhibitors for treatment of basal cell carcinoma, limited clinical data is available. This case study describes a patient being treated with nivolumab for a responsive non-small cell carcinoma and his subsequent development and relapse of a basal cell carcinoma tumor."

Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma

Ian Lai, Srividya Swaminathan, Virginie Baylot, Adriane Mosley, Renumathy Dhanasekaran, Meital Gabay and Dean W. Felsher
Journal for ImmunoTherapy of Cancer, 6:125 (20 November 2018)
Research Article

From the Authors

"Our recent work has suggested that oncogenes such as MYC are playing a direct role in regulating the immune microenvironment. Now, we have found that we can utilize nanotechnology to deliver IL-12 to restore the immune response against MYC driven liver cancer. We believe that more generally insight into the molecular etiology of cancer can guide immune therapy to treat cancer."

Dean W. Felsher, MD, PhD — Stanford University School of Medicine

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors

Vivek Verma, Tanja Sprave, Waqar Haque, Charles B. Simone II, Joe Y. Chang, James W. Welsh and Charles R. Thomas Jr
Journal for ImmunoTherapy of Cancer, 6:128 (23 November 2018)
Review

From the Authors

"This study is the only known summative analysis of the economic impact of influential but expensive therapies such as immune checkpoint inhibitors."

Vivek Verma, PhD — GRU Cancer Center

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies

Aixa E. Soyano, Bhagirathbhai Dholaria, Julian A. Marin-Acevedo, Nancy Diehl, David Hodge, Yan Luo, Rami Manochakian, Saranya Chumsri, Alex Adjei, Keith L. Knutson and Yanyan Lou
Journal for ImmunoTherapy of Cancer, 6:129 (23 November 2018)
Research Article

From the Authors

"Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). To date, no blood biomarkers have been identified in NSCLC to predict clinical outcomes of treatment with anti-PD-1 antibodies. We performed an analysis of 157 patients with advanced NSCLC treated with anti-PD-1 antibodies at our institution. We found that increased baseline ANC: ALC ratio and M: L ratio before initiation of anti-PD1 antibodies were associated with poor PFS and OS in advanced NSCLC patients. The potential predictive value of these readily available biomarkers might help with risk stratification and treatment strategies."

Yanyan Lou, MD — Mayo Clinic

Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma

Leandro J. C. Oliveira, Aline B. L. Gongora, Felipe G. Barbosa, Carlos H. dos Anjos and Rodrigo R. Munhoz
Journal for ImmunoTherapy of Cancer, 6:130 (27 November 2018)
Case Report

Excerpt:

"We present a case of a patient developing an atypical pattern of response, marked by bone pseudoprogression during therapy with nivolumab for advanced CSCC, followed by sustained response."

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy

Natalie J. Miller, Candice D. Church, Steven P. Fling, Rima Kulikauskas, Nirasha Ramchurren, Michi M. Shinohara, Harriet M. Kluger, Shailender Bhatia, Lisa Lundgren, Martin A. Cheever, Suzanne L. Topalian and Paul Nghiem
Journal for ImmunoTherapy of Cancer, 6:131 (27 November 2018)
Research Article

From the Authors

"Merkel cell carcinoma (MCC) patients have a high overall response rate (56%) to anti-PD-1 therapy. Approximately 80% of all MCCs are driven by viral oncoproteins from the Merkel cell polyomavirus leading to shared tumor antigens among most patients. We took advantage of this unique opportunity to assess the B and T cell immune responses in MCC patients receiving anti-PD-1 therapy. We found striking differences in the nature of immune response to virus-positive as compared to virus-negative MCC, despite both subtypes having excellent response rates."

Paul Nghiem, MD, PhD — University of Washington

Soluble immune checkpoints in cancer: production, function and biological significance

Daqian Gu, Xiang Ao, Yu Yang, Zhuo Chen and Xiang Xu
Journal for ImmunoTherapy of Cancer, 6:132 (27 November 2018)
Review

Excerpt:

"The natural soluble forms of receptors and ligands are important components of immune regulation, although their definitive mechanisms of action have not been determined. In this review, we selected sPD-1, sPD-L1, sPD-L2, sCTLA-4, sCD80, sCD86, sB7-H3 and sCD137 for analysis. All of these molecules may play important roles in cancer."

Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results

Jacek Mackiewicz, Tomasz Burzykowski, Dariusz Iżycki and Andrzej Mackiewicz
Journal for ImmunoTherapy of Cancer, 6:134 (29 November 2018)
Clinical Trials Monitor

From the Authors

"In the currently presented analysis we observed that treatment beyond recurrence with initial re-induction (8 doses of AGI-101H every 2 weeks), and followed by maintenance every 4 weeks was linked with reduction of mortality hazard in both Trial 3 and Trial 5, though it reached statistical significance only in Trial 5. These observations show that some patients might benefit from treatment beyond recurrence/progression with additional re-induction."

Immunotherapy utilizing the combination of natural killer– and antibody dependent cellular cytotoxicity (ADCC)–mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition

Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong and James W. Hodge
Journal for ImmunoTherapy of Cancer, 6:133 (29 November 2018)
Research Article

From the Authors

"We identified an off-target activity of the PARP inhibitor Olaparib that could be exploited for immunotherapy. Olaparib significantly increased tumor cell sensitivity to NK-mediated killing and anti-PD-L1 or anti-EGFR ADCC in both BRCA WT and BRCA mutant tumor cells, independent of PD-L1 or EGFR) modulation, mediated by upregulation of TRAIL-R2. These studies support the combined use of NK- and ADCC-mediating agents with PARPi in BRCA mutant and WT carcinoma."

James W. Hodge, PhD, MBA — National Cancer Institute

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Yaxiong Zhang, Huaqiang Zhou and Li Zhang
Journal for ImmunoTherapy of Cancer, 6:135 (3 December 2018)
Commentary

From the Authors

"There is no head-to-head comparison of pembrolizumab plus chemotherapy vs. atezolizumab plus chemotherapy. Therefore, we performed an indirect comparison of KEYNOTE-407 and IMpower131 to explore the optimal choice of anti-PD-(L)1 treatment for advanced squamous NSCLC in combination with chemotherapy."

SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art

Lisa H. Butterfield, Mary L. Disis, Bernard A. Fox, David R. Kaufman, Samir N. Khleif, Ena Wang and on behalf of the Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers
Journal for ImmunoTherapy of Cancer, 6:138 (4 December 2018)
Review

From the Authors

"The identification of useful biomarkers represents a worldwide effort in clinical immune oncology to guide patient selection, enhance chances of therapeutic success and improve therapeutic window by decreasing unwanted toxicities. This report summarizes the opinion of global experts on the implementation of state of the art technologies and the identification of challenges limited the advancement of the field. In addition, it highlights the new initiatives driven by the SITC Biomarkers Committee."

Ena Wang, MD — Allogene

Oncolytic virus immunotherapy: future prospects for oncology

Junaid Raja, Johannes M. Ludwig, Scott N. Gettinger, Kurt A. Schalper and Hyun S. Kim
Journal for ImmunoTherapy of Cancer, 6:140 (4 December 2018)
Review

From the Authors

"In the time of new and promising immuno-oncologic therapies, image-guided oncoviral therapy offers another avenue of hope for patients with previously unresectable, advanced malignancies not amenable to other classical oncologic therapies. The idea of image directed, locally delivered, molecular therapy supplemented by immune conditioning by which the delivered particles induce an indirect native tissue response is a patient-centered and personalized approach."

Hyun S. Kim, MD — Yale School of Medicine

Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells

Jiao Wang, Kyle B. Lupo, Andrea M. Chambers and Sandro Matosevic
Journal for ImmunoTherapy of Cancer, 6:136 (4 December 2018)
Research Article

From the Authors

"Our study shows that natural killer (NK) cells to express chimeric antigen receptors (CARs) against NKG2D ligands on cancer cells, show enhanced anti-tumor immunity and can mediate more efficient killing of solid tumors when combined with targeting of the purinergic cascade via CD73 in vivo. CD73, expressed on many solid tumors including glioblastoma and lung cancer, is a key component of the enzymatic cascade involved in the generation of extracellular adenosine, which we show leads to impaired NK cell effector function. Here, by combining CAR-NK cells engineered non-virally using a piggyBac vector system with CD73 targeting, we show, for the first time, both an improved immunotherapeutic effect and enhanced intratumoral penetration of these engineered NK cells in vivo."

Sandro Matosevic, PhD — Purdue University

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June and Michael R. Bishop
Journal for ImmunoTherapy of Cancer, 6:137 (4 December 2018)
Review

From the Authors

"Our purpose here is to discuss the history of CAR T therapies, review the current toxicity management protocols, and provide an overview of in-development technologies for clinicians who will be treating patients with or referring patients for these groundbreaking therapies."

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee and William L. Dahut
Journal for ImmunoTherapy of Cancer, 6:141 (4 December 2018)
Research Article

From the Authors

"It’s exciting to see deep prolonged responses in men with castration-resistant prostate cancer when combining durvalumab with olaparib. This was particularly strikingly in men with germline or somatic DDR abnormalities. Additional patients will be studied to better define the activity and to help elucidate the biology."

William L. Dahut, MD — National Cancer Institute, NIH

Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients

Iva Truxova, Lenka Kasikova, Michal Hensler, Petr Skapa, Jan Laco, Ladislav Pecen, Lucie Belicova, Ivan Praznovec, Michael J. Halaska, Tomas Brtnicky, Eva Salkova, Lukas Rob, Roman Kodet, Jeremy Goc, Catherine Sautes-Fridman, Wolf Herman Fridman, Ales Ryska, Lorenzo Galluzzi, Radek Spisek and Jitka Fucikova
Journal for ImmunoTherapy of Cancer, 6:139 (4 December 2018)
Research Article

Excerpt:

"By combining IHC and biomolecular analyses, we comprehensively documented for the first time the influence of both mature DCs [dendritic cells] and CD20+ B cells on the establishment of the immune contexture of HGSC [high-grade serous ovarian carcinoma]."


Highly Accessed Articles

SITC_logo.jpg

Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement

Apostolia M. Tsimberidou, Laura A. Levit, Richard L. Schilsky, Steven D. Averbuch, Daniel Chen, John M. Kirkwood, Lisa M. McShane, Elad Sharon, Kathryn F. Mileham and Michael A. Postow
Journal for ImmunoTherapy of Cancer 2018, 6:108 (19 October 2018)

SITC_logo.jpg

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang and Hans J Hammers
Journal for ImmunoTherapy of Cancer 2018, 6:109 (22 October 2018)

SITC_logo.jpg

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment

Yasuko Tada, Yosuke Togashi, Daisuke Kotani, Takeshi Kuwata, Eichi Sato, Akihito Kawazoe, Toshihiko Doi, Hisashi Wada, Hiroyoshi Nishikawa and Kohei Shitara
Journal for ImmunoTherapy of Cancer 2018, 6:106 (11 October 2018)


Submit Your Research to JITC

SITC Members Receive Complimentary Article Processing Charges in 2018*
SITC members and non-members are invited to submit manuscripts to the society's official journal.
Article Types
JITC Editor-in-Chief
Pedro J. Romero, MD – University of Lausanne

Section Editors

  • Basic Tumor Immunology: Cornelis J.M. Melief, MD, PhD – ISA Therapeutics BV
  • Case Reports: Alfred Zippelius, MD – University Hospital Basel
  • Clinical/Translational Cancer Immunology: James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
  • Clinical Trials Monitor: Leisha A. Emens, MD, PhD – UPMC Hillman Cancer Center
  • Commentary/Editorials: Christian Capitini, MD – University of Wisconsin - Madison
  • Guidelines and Consensus Statements: Robert L. Ferris, MD, PhD – UPMC Hillman Cancer Center
  • Immunotherapy Biomarkers: Lisa H. Butterfield, PhD – University of Pittsburgh Cancer Institute
  • Reviews: Sandra Demaria, MD – Weill Cornell Medical College; Thomas F. Gajewski, MD, PhD – University of Chicago

To view the full editorial board, please click here.

*As a way to thank the dedicated society members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, one article per SITC member is eligible for waived article processing charges through 2018. To take advantage of this benefit valued at more than $2,400, authors must contact JITC Managing Editor Andrea Kunz at JITCEditor@sitcancer.org or 1-414-271-2456 prior to submission to obtain a discount code and instructions.

Join_SITC_JITC.png?r=1499893816711 Become a Member!

Journal for ImmunoTherapy of Cancer (JITC) is the official, online, open access journal of the Society for Immunotherapy of Cancer (SITC) and considered BMC’s premier cancer immunotherapy journal. JITC welcomes basic, translational and clinical research and literature reviews on any aspect of tumor immunology and cancer immunotherapy. Topics of interest include tumor-host interactions, immune biomarkers, novel therapeutics, and immune-related toxicity.  The journal’s full collection, including its seminal guidelines and consensus statements, advances the rapidly evolving field of cancer immunotherapy through dissemination of rigorous peer-reviewed research.